AR096729A1 - Derivados terapéuticamente activos de estratien-tiazol - Google Patents
Derivados terapéuticamente activos de estratien-tiazolInfo
- Publication number
- AR096729A1 AR096729A1 ARP140102399A ARP140102399A AR096729A1 AR 096729 A1 AR096729 A1 AR 096729A1 AR P140102399 A ARP140102399 A AR P140102399A AR P140102399 A ARP140102399 A AR P140102399A AR 096729 A1 AR096729 A1 AR 096729A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- perhaloalkyl
- haloalkyl
- formula
- Prior art date
Links
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 abstract 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 239000003270 steroid hormone Substances 0.000 abstract 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- 125000002373 5 membered heterocyclic group Chemical group 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 abstract 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0042—Nitrogen only
- C07J71/0052—Nitrogen only at position 16(17)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
- C07J71/0036—Nitrogen-containing hetero ring
- C07J71/0057—Nitrogen and oxygen
- C07J71/0068—Nitrogen and oxygen at position 16(17)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a los compuestos de la fórmula (1) y sus sales farmacéuticamente aceptables. La presente además se refiere a su uso como inhibidores de 17b-HSD1 y en el tratamiento o la prevención de enfermedades o trastornos que dependen de las hormonas esteroides, tales como enfermedades o trastornos que dependen de las hormonas esteroides que requieren la inhibición de la enzima 17b-HSD1 y/o que requieren la disminución de la concentración de estradiol endógeno. La presente también se refiere a la preparación de los compuestos antes mencionados y a composiciones farmacéuticas que comprenden como principio activo uno o más de los compuestos antes mencionados o sus sales farmacéuticamente aceptables. Reivindicación 1: Un compuesto de la fórmula (1) en donde (i-a) R² y R⁴ se seleccionan cada uno independientemente del grupo que consiste en H, halógeno, alquilo C₁₋₆, haloalquilo C₁₋₃, perhaloalquilo C₁₋₃, CN, NO₂, N₃, N(R)₂, (CH₂)ₙN(R)₂, OR, (CH₂)ₙOR, CO₂R, CONHR, NHCOR, C(=NH)R, C(=N-OH)R y COR; R³ se selecciona del grupo que consiste en H, alquilo C₁₋₆, haloalquilo C₁₋₃, perhaloalquilo C₁₋₃, N(R)₂, N₃, y OR³, en donde R³ se selecciona del grupo que consiste en R, bencilo, succinilo, glucuronilo opcionalmente acilado, (CH₂)ₙOH, SO₂OH, SO₂R, tosilo, SO₂N(R)₂, PO(OR)₂, COOR, C(O)N(R)₂, C(O)(CH₂)ₙN(R)₂, C(O)CH₂NHC(O)R, C(O)CH₂NHC(O)OR y C(O)R; en donde R es H o alquilo C₁₋₆, haloalquilo C₁₋₃, o perhaloalquilo C₁₋₆, o cuando son parte de cualquier N(R)₂ ambas R junto con el nitrógeno al cual se unen pueden formar un anillo heterocíclico aromático o alifático de 5 a 6 miembros que comprende 1 ó 2 heteroátomos, cada uno independientemente seleccionado entre N y O; R es alquilo C₁₋₆, haloalquilo C₁₋₃, o perhaloalquilo C₁₋₃; R es alquilo C₁₋₁₈, alquenilo C₂₋₁₈, -(CH₂)ₙ-cicloalquilo C₃₋₆, o a fenilo opcionalmente sustituido; y n es 1 ó 2; o (i-b) R² y R³ o R³ y R⁴, junto con los átomos de carbono del anillo a los cuales se unen, forman un anillo heterocíclico de 5 miembros aromático o no saturado que comprende 1 ó 2 heteroátomos cada uno independientemente seleccionado entre N y O, opcionalmente sustituidos con metilo u oxo; y R⁴ o R², respectivamente, es H y halógeno; (ii-a) R⁵ y R⁶ son cada uno H o R⁵ y R⁶ forman juntos =CH-OH; y R⁷ se selecciona del grupo que consiste en ureido RO-alquilenilo C₁₋₃, RS-alquilenilo C₁₋₃, R₂N-alquilenilo C₁₋₃, y OR⁷, en donde R⁷ se selecciona del grupo que consiste en H, alquilo C₁₋₆, alquenilo C₁₋₆, y carboxi-alquilenilo C₁₋₃; o (ii-b) R⁵ y R⁶ y =NR⁷ forman junto con los carbonos a los que se unen una estructura de fórmula (2) que se selecciona de los restos de fórmula (3) ó (4), en donde X es O ó NH; o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20135694 | 2013-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096729A1 true AR096729A1 (es) | 2016-01-27 |
Family
ID=51220584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102399A AR096729A1 (es) | 2013-06-25 | 2014-06-25 | Derivados terapéuticamente activos de estratien-tiazol |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9663549B2 (es) |
| EP (1) | EP3013846B1 (es) |
| JP (1) | JP6556125B2 (es) |
| KR (1) | KR20160042873A (es) |
| CN (1) | CN105518015B (es) |
| AR (1) | AR096729A1 (es) |
| AU (1) | AU2014300894A1 (es) |
| BR (1) | BR112015031846A8 (es) |
| CA (1) | CA2914667A1 (es) |
| EA (1) | EA201690077A1 (es) |
| HK (1) | HK1217495A1 (es) |
| IL (1) | IL242968A0 (es) |
| MA (1) | MA38694B1 (es) |
| MX (1) | MX2015017879A (es) |
| SG (1) | SG11201510251TA (es) |
| TN (1) | TN2015000555A1 (es) |
| TW (1) | TW201534612A (es) |
| WO (1) | WO2014207310A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6545266B2 (ja) * | 2014-12-23 | 2019-07-17 | フォレンド ファーマ リミテッド | １７β‐ＨＳＤ１抑制剤のプロドラッグ |
| EP3237431B1 (en) * | 2014-12-23 | 2019-03-20 | Forendo Pharma Ltd | Prodrugs of 17.beta.-hsd1 -inhibitors |
| CZ307437B6 (cs) | 2016-06-07 | 2018-08-22 | Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. | 15β-substituované deriváty estronu jako selektivní inhibitory 17β-hydroxysteoiddehydrogenáz |
| DK3634975T3 (da) * | 2017-06-08 | 2024-05-27 | Organon R&D Finland Ltd | 17-oximer af 15.beta.-[3-propanamido]-substituerede estra-1,3,5(10)-trien-17-oner til anvendelse i inhibition af 17.beta.-hydroxysteroid-dehydrogenaser |
| EP3891167B1 (en) * | 2018-12-05 | 2024-11-13 | Organon R&D Finland Oy | Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 |
| CN114644673B (zh) * | 2020-12-19 | 2023-12-26 | 上海喀露蓝科技有限公司 | 一种雌二醇衍生物、其制备方法及其在医药上的用途 |
| AR133544A1 (es) * | 2023-08-15 | 2025-10-08 | Univ Laval | INHIBIDORES IRREVERSIBLES DE 17b-HSD1 |
| CN120607578A (zh) * | 2024-03-08 | 2025-09-09 | 长春金赛药业有限责任公司 | 17β-HSD1抑制剂化合物、药物组合物及其应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2323089A1 (en) | 1998-03-11 | 1999-09-16 | Endorecherche, Inc. | Inhibitors of type 5 and type 3 17.beta.-hydroxysteroid dehydrogenase and methods for their use |
| DE69935335T2 (de) | 1998-08-07 | 2007-11-22 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Pyrazole als modulatoren des östrogenrezeptors |
| GB9929302D0 (en) | 1999-12-11 | 2000-02-02 | Univ Cardiff | Benzyl tetralins compositions and uses thereof |
| AU2001288386B2 (en) * | 2000-11-27 | 2006-11-02 | Entremed, Inc. | 2-substituted estrogens as antiangiogenic agents |
| AR036492A1 (es) | 2001-09-06 | 2004-09-15 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes |
| ES2347643T3 (es) | 2001-10-17 | 2010-11-03 | Schering Corporation | Piperin- y piperazinacetamidas como inhibidores de 17beta hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgenos. |
| US6750248B2 (en) | 2001-11-09 | 2004-06-15 | National University Of Singapore | Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
| JP4614770B2 (ja) | 2002-11-18 | 2011-01-19 | シェーリング コーポレイション | アンドロゲン依存性疾患を処置するための１７β−ヒドロキシステロイドデヒドロゲナーゼタイプ３インヒビター |
| AU2003293555A1 (en) | 2002-12-17 | 2004-07-29 | Schering Corporation | 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| WO2004085345A2 (en) | 2003-03-21 | 2004-10-07 | Yale University | 15α-SUBSTITUTED ESTRADIOL CARBOXYLIC ACID ESTERS AS LOCALLY ACTIVE ESTROGENS |
| GB0306718D0 (en) * | 2003-03-24 | 2003-04-30 | Sterix Ltd | Compound |
| US7465739B2 (en) | 2003-06-10 | 2008-12-16 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
| US7754709B2 (en) | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
| TWI331154B (en) | 2003-11-12 | 2010-10-01 | Solvay Pharm Gmbh | Novel 17-hydroxysteroid dehydrogenase type i inhibitors |
| US7378426B2 (en) | 2004-03-01 | 2008-05-27 | Bristol-Myers Squibb Company | Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 |
| DE102004032674A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte Estra-1,3,5(10)-trien-17-one als Inhibitoren der 17β-Hydroxysteroiddehydrogenase Typ 1 |
| DE102004032673A1 (de) | 2004-07-02 | 2006-01-26 | Schering Ag | Neue 2-substituierte D-Homo-estra-1,3,5(10)-triene als Inhibitoren der 17ß-Hydroxysteroiddehydrogenase Typ 1 |
| UA89964C2 (ru) | 2004-09-08 | 2010-03-25 | Н.В. Органон | 15β-ЗАМЕЩЕННЫЕ СТЕРОИДЫ, КОТОРЫЕ ИМЕЮТ СЕЛЕКТИВНУЮ ЭСТРОГЕННУЮ АКТИВНОСТЬ |
| US8030298B2 (en) * | 2005-05-26 | 2011-10-04 | Abbott Products Gmbh | 17β-HSD1 and STS inhibitors |
| ES2388297T3 (es) * | 2005-05-26 | 2012-10-11 | Abbott Products Gmbh | Inhibidores de 17-HSD1 y STS |
| WO2008034796A2 (en) | 2006-09-19 | 2008-03-27 | Solvay Pharmaceuticals Gmbh | Estratriene derivatives and their uses as 17beta-hydr0xyster0id dehydrogenase inhibitors |
| US8288367B2 (en) * | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| AU2007327653B2 (en) * | 2006-11-30 | 2013-04-18 | Solvay Pharmaceuticals Gmbh | Substituted estratrien derivatives as 17beta HSD inhibitors |
-
2014
- 2014-06-25 MX MX2015017879A patent/MX2015017879A/es unknown
- 2014-06-25 SG SG11201510251TA patent/SG11201510251TA/en unknown
- 2014-06-25 EP EP14742254.7A patent/EP3013846B1/en active Active
- 2014-06-25 WO PCT/FI2014/050518 patent/WO2014207310A1/en not_active Ceased
- 2014-06-25 JP JP2016522679A patent/JP6556125B2/ja active Active
- 2014-06-25 AR ARP140102399A patent/AR096729A1/es unknown
- 2014-06-25 TN TN2015000555A patent/TN2015000555A1/en unknown
- 2014-06-25 AU AU2014300894A patent/AU2014300894A1/en not_active Abandoned
- 2014-06-25 BR BR112015031846A patent/BR112015031846A8/pt not_active IP Right Cessation
- 2014-06-25 CN CN201480046108.2A patent/CN105518015B/zh active Active
- 2014-06-25 CA CA2914667A patent/CA2914667A1/en not_active Abandoned
- 2014-06-25 MA MA38694A patent/MA38694B1/fr unknown
- 2014-06-25 US US14/392,291 patent/US9663549B2/en active Active
- 2014-06-25 HK HK16105581.6A patent/HK1217495A1/zh unknown
- 2014-06-25 EA EA201690077A patent/EA201690077A1/ru unknown
- 2014-06-25 TW TW103121874A patent/TW201534612A/zh unknown
- 2014-06-25 KR KR1020167001998A patent/KR20160042873A/ko not_active Withdrawn
-
2015
- 2015-12-06 IL IL242968A patent/IL242968A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015017879A (es) | 2017-03-01 |
| EA201690077A1 (ru) | 2016-09-30 |
| SG11201510251TA (en) | 2016-01-28 |
| MA38694B1 (fr) | 2020-01-31 |
| BR112015031846A8 (pt) | 2018-03-06 |
| AU2014300894A1 (en) | 2016-01-28 |
| BR112015031846A2 (pt) | 2017-07-25 |
| JP6556125B2 (ja) | 2019-08-07 |
| KR20160042873A (ko) | 2016-04-20 |
| JP2016523886A (ja) | 2016-08-12 |
| CN105518015A (zh) | 2016-04-20 |
| US20170081357A1 (en) | 2017-03-23 |
| IL242968A0 (en) | 2016-02-01 |
| US9663549B2 (en) | 2017-05-30 |
| TN2015000555A1 (en) | 2017-04-06 |
| EP3013846A1 (en) | 2016-05-04 |
| HK1217495A1 (zh) | 2017-01-13 |
| MA38694A2 (fr) | 2017-12-29 |
| EP3013846B1 (en) | 2017-08-09 |
| TW201534612A (zh) | 2015-09-16 |
| CA2914667A1 (en) | 2014-12-31 |
| CN105518015B (zh) | 2017-09-15 |
| WO2014207310A1 (en) | 2014-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR096729A1 (es) | Derivados terapéuticamente activos de estratien-tiazol | |
| CO2018003565A2 (es) | Compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53 | |
| PE20191540A1 (es) | DERIVADOS DE PIRROLO [1,2-b] PIRIDAZINA | |
| AR078535A1 (es) | Derivados de pirrolo[2,3-b]piridina ligandos de receptores estrogenicos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la osteoporosis y enfermedades del sistema nervioso central, entre otras | |
| MX385158B (es) | Derivados indol para uso en medicina. | |
| AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
| MX2017002260A (es) | Nuevos compuestos de espiro[3h-indol-3,2´-pirrolidin]-2(1h)-ona y derivados como inhibidores de mdm2-p53. | |
| AR069510A1 (es) | Arilo y heteroarilo imidazo[1,5-a]pirazinas fusionadas como inhibidores de la fosfodiesterasa 10 | |
| AR096727A1 (es) | Derivados terapéuticamente activos de estratrien-tiazol | |
| AR084070A1 (es) | Inhibidores del bromodominio y usos de los mismos | |
| MX382331B (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3f] isoquinolina útiles en el tratamiento del cáncer. | |
| AR044116A1 (es) | Compuestos derivados de 5,7 diamino pirazolo [4,3-d] pirimidinas, intermediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la fabricacion de medicamentos. | |
| MX2019010736A (es) | Inhibidor del antigeno de superficie del virus de la hepatitis b. | |
| AR106037A1 (es) | Moduladores de la proteína core de la hepatitis b | |
| AR101175A1 (es) | Imidazopiridinas e imidazopirazinas como inhibidores de lsd1 | |
| AR110753A1 (es) | Inhibidores selectivos de jak1 | |
| AR096728A1 (es) | Derivados de estratrieno-tiazol terapéuticamente activos | |
| CR20170250A (es) | TETRAHIDRO-PIRIDO[3,4-b]INDOLES MODULADORES DE RECEPTORES DE ESTRÓGENOS Y USOS DE LOS MISMOS | |
| AR126255A1 (es) | Derivados de imidazotriazina como moduladores de il-17 | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| TN2016000503A1 (en) | Pyrazolopyridines and pyrazolopyrimidines | |
| PE20170303A1 (es) | Derivados de la indolizina como inhibidores de las fosfoinositido-3 quinasas | |
| AR107864A1 (es) | ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS | |
| AR102213A1 (es) | Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades | |
| RU2014121205A (ru) | Производные азолов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |